Solid Biosciences (SLDB) EBIT Margin (2022)

Solid Biosciences' (SLDB) quarterly EBIT Margin came in at 411.44% in Q2 2022.

Solid Biosciences (SLDB) EBIT Margin (2022) Analysis & Trends

Solid Biosciences has disclosed EBIT Margin across 1 years of filings, most recently posting 411.44% for Q2 2022.

EBIT Margin for Q2 2022 came in at 411.44%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was 1857.21% (down 43984.0% YoY), and the FY2022 annual result was 1315.2%, down 78470.0% from the prior year.
EBIT Margin came in at 411.44% for Q2 2022 at Solid Biosciences.
In the past five years, EBIT Margin ranged from a high of 411.44% in Q2 2022 to a low of 411.44% in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Alterity Therapeutics	860,679.92 Bn	860,679.89 Bn	-	-
2	Belite Bio	55,284.00 Bn	55,284.00 Bn	-	-
3	Quantum Biopharma	16,206.94 Bn	16,206.93 Bn	-	-
4	Legend Biotech	3,318.00 Bn	3,317.71 Bn	242.10 Mn	-6.43%
5	Akari Therapeutics	1,543.84 Bn	1,543.84 Bn	-	-
6	Evaxion A	1,449.11 Bn	1,449.09 Bn	-	-
7	Psyence Biomedical	216.99 Bn	216.98 Bn	-	-
8	Vertex Pharmaceuticals	115.22 Bn	107.97 Bn	2.59 Bn	38.10%
9	Abivax	90.58 Bn	90.58 Bn	-	-
10	Solid Biosciences	777.47 Mn	396.79 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2022	-411.44%